» Articles » PMID: 24735761

Understanding the Hysteresis Loop Conundrum in Pharmacokinetic/pharmacodynamic Relationships

Overview
Specialties Pharmacology
Pharmacy
Date 2014 Apr 17
PMID 24735761
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Hysteresis loops are phenomena that sometimes are encountered in the analysis of pharmacokinetic and pharmacodynamic relationships spanning from pre-clinical to clinical studies. When hysteresis occurs it provides insight into the complexity of drug action and disposition that can be encountered. Hysteresis loops suggest that the relationship between drug concentration and the effect being measured is not a simple direct relationship, but may have an inherent time delay and disequilibrium, which may be the result of metabolites, the consequence of changes in pharmacodynamics or the use of a non-specific assay or may involve an indirect relationship. Counter-clockwise hysteresis has been generally defined as the process in which effect can increase with time for a given drug concentration, while in the case of clockwise hysteresis the measured effect decreases with time for a given drug concentration. Hysteresis loops can occur as a consequence of a number of different pharmacokinetic and pharmacodynamic mechanisms including tolerance, distributional delay, feedback regulation, input and output rate changes, agonistic or antagonistic active metabolites, uptake into active site, slow receptor kinetics, delayed or modified activity, time-dependent protein binding and the use of racemic drugs among other factors. In this review, each of these various causes of hysteresis loops are discussed, with incorporation of relevant examples of drugs demonstrating these relationships for illustrative purposes. Furthermore, the effect that pharmaceutical formulation has on the occurrence and potential change in direction of the hysteresis loop, and the major pharmacokinetic / pharmacodynamic modeling approaches utilized to collapse and model hysteresis are detailed.

Citing Articles

Clinical Effects and Pharmacokinetic Profile of Intramuscular Dexmedetomidine (10 μg/kg) in Cats.

Fernandes N, Passos Y, Arcoverde K, Mouta A, Paiva T, Oliveira K Animals (Basel). 2024; 14(15).

PMID: 39123800 PMC: 11310985. DOI: 10.3390/ani14152274.


An integrated strategy to evaluate active substances of Astragali Radix-Carthami Flos combination on the treatment of cerebral ischemia reperfusion injury based on TQSM polypharmacokinetics and pharmacodynamics.

Zeng Q, Li C, Xu S, He Y J Food Drug Anal. 2024; 31(4):711-738.

PMID: 38526820 PMC: 10962676. DOI: 10.38212/2224-6614.3477.


The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.

Knuijver T, Ter Heine R, Schellekens A, Heydari P, Lucas L, Westra S J Psychopharmacol. 2024; 38(5):481-488.

PMID: 38519421 PMC: 11102648. DOI: 10.1177/02698811241237873.


A Review of the Lidocaine in the Perioperative Period.

Silva A, Mourao J, Vale N J Pers Med. 2023; 13(12).

PMID: 38138926 PMC: 10744742. DOI: 10.3390/jpm13121699.


Pharmacokinetic-Pharmacodynamic Modeling of Midazolam in Pediatric Surgery.

Flores-Perez C, Moreno-Rocha L, Chavez-Pacheco J, Noguez-Mendez N, Flores-Perez J, Ortiz-Marmolejo D Pharmaceutics. 2023; 15(11).

PMID: 38004544 PMC: 10674765. DOI: 10.3390/pharmaceutics15112565.


References
1.
Elliott H, Vincent J, MEREDITH P, Reid J . Relationship between plasma prazosin concentration and alpha-antagonism in humans: comparison of conventional and rate-controlled (Oros) formulations. Clin Pharmacol Ther. 1988; 43(5):582-7. DOI: 10.1038/clpt.1988.77. View

2.
Ohtani H, Taninaka C, Hanada E, Kotaki H, Sato H, Sawada Y . Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother. 2000; 44(10):2630-7. PMC: 90127. DOI: 10.1128/AAC.44.10.2630-2637.2000. View

3.
Luckow V, Della Paschoa O . PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop. Int J Clin Pharmacol Ther. 1997; 35(10):418-25. View

4.
Yagi N, Kiuchi T, Satoh H, Ishikawa Y, Takada M, Sekikawa H . Bioavailability and diuretic effect after administration of retarded capsules of bumetanide in human subjects. Biol Pharm Bull. 1999; 22(3):275-80. DOI: 10.1248/bpb.22.275. View

5.
Tonussi C, Ferreira S . Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization. Eur J Pharmacol. 1994; 251(2-3):173-9. DOI: 10.1016/0014-2999(94)90398-0. View